(1-cyclopropylethenyl)boronic acid | 1121058-18-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 英文名称: (1-cyclopropylethenyl)boronic acid
• 英文别名: (1-cyclopropylvinyl)boronic acid；1-cyclopropylethenylboronic acid
• CAS: 1121058-18-1
• 化学式: C₅H₉BO₂
• 分子量: 111.936
• InChiKey: YTSAWKWNDHDKNM-UHFFFAOYSA-N

物化性质

• 沸点：
  231.7±23.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.04
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (1-cyclopropylethenyl)boronic acid 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 3.0h， 生成 2-(5-Chloro-2,4-difluorophenyl)-6-(1-cyclopropylethenyl)-3-fluoropyridine
  参考文献：
  名称：

  [EN] ANTIVIRAL COMPOUNDS
  [FR] COMPOSÉS ANTIVIRAUX

  摘要：

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  公开号：

  WO2023211997A1

文献信息

• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：[en]ENANTA PHARMACEUTICALS, INC.

  公开号：WO2023211997A1

  公开（公告）日：2023-11-02

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.